ALK- sALCL (n = 76)		Non-sALCL (n = 38)		Combined (N = 114)
	SCT (n = 27)	No SCT (n = 49)	SCT (n = 11)	No SCT (n = 27)	SCT* (n = 38)	No SCT (n = 76)
Estimated PFS at 3 years, % (95% CI)	80.4 (59.1, 91.4)	56.9 (40.6, 70.3)	70.1 (32.3, 89.5)	46.7 (26.7, 64.4)	76.1 (56.9, 87.6)	53.3 (40.7, 64.3)
Univariate HR (95% CI)	0.49 (0.19, 1.27)	0.36 (0.10, 1.26)	0.38 (0.18, 0.82)
Multivariate HR (95% CI) adjusted for:
Age†	0.54 (0.20, 1.45)	0.32 (0.09, 1.15)	0.39 (0.18, 0.86)
Region‡	0.47 (0.18, 1.22)	0.37 (0.10, 1.33)	0.38 (0.18, 0.82)
Age† + Region‡	0.52 (0.19, 1.41)	0.32 (0.09, 1.19)	0.39 (0.18, 0.86)
Median follow-up, months (95% CI)	29.9 (24.2, 36.1)	41.6 (29.8, 42.0)	49.8 (21.2, 54.0)	42.6 (29.5, 53.9)	35.9 (24.5, 41.9)	41.6 (33.2, 42.1)

This research was originally published in Blood. Savage KJ et al. An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant. Blood. 2019;134(Supplement 1):p464. © The American Society of Hematology. Table presents HR of PFS for patients who achieved CR on A+CHP, SCT versus no SCT; HR<1 favours SCT; all HRs were stratified for baseline IPI score (0-1; 2-3; 4-5). PFS was measured from randomisation to progressive disease, death, or receipt of subsequent systemic chemotherapy to treat residual or progressive PTCL as determined by the investigator, whichever came first. Consolidative SCT was not considered an event. * Includes 2 allogeneic SCTs. † <65; ≥65 years. ‡ Non-Asia (rest of world); Asia (Taiwan, Japan, and South Korea). ¶ Median follow-up is calculated for PFS using the Kaplan-Meier method of switching the PFS event and censored status.